Skip to content
Concord Biotech logo

Concord Biotech

CONCORDBIO NSE
₹655.50 +41.50 (+6.76%)
P/E
24.33
View as Markdown
MCP
Close 4 Nov 2026 ₹655.50 −50.20 −7.11% 1Y
Start ₹705.70

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Standalone · TTM

ROCE
17.40%
Debt to Equity
0.00
EPS (TTM)
₹26.94
Book Value
₹198.42
Market Cap
—
P/E (TTM)
24.33
P/B
3.30
ROE
12.60%
Dividend Yield
1.23%
EBITDA
₹420 Cr
52W High
₹807.50
52W Low
₹493.50
Day Range
₹594.60 – ₹662.00
Volume
3,55,637

Peer Comparison

Healthcare › Pharmaceuticals

Concord Biotech peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Concord Biotech (this company)
₹655.5024.33₹12,834 Cr3.301.23%12.60%17.40%₹1,112 Cr₹282 Cr
Median 8 companies₹1,587.7037.20₹1,25,337 Cr4.570.70%16.25%17.60%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

55 Good

Data confidence 100/100

Category scores

Quality
69
Strong
Returns, margins, earnings quality 22% weight
Valuation
67
Strong
Cheap vs sector & own history 24% weight
Growth
9
Poor
Sales & profit trajectory 9% weight
Financial Health
84
Strong
Solvency, leverage, coverage 9% weight
Momentum
41
Weak
Trend strength, vol-adjusted 12% weight
Ownership
62
Good
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company has reduced debt.
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 28.2%

Weaknesses

2
  • The company has delivered a poor sales growth of 11.3% over past five years.
  • Company has high debtors of 159 days.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBearish856
OscillatorsBearish351
Moving AveragesNeutral505

Key readings

RSI (14)
49.17
Neutral
MACD (12,26,9)
−21.90
Bearish
SMA (50)
699.72
Bearish
SMA (200)
633.13
Bullish

As of

Analyst Rating

Based on 3 analysts
BUY67%

2 of 3 analysts rate Buy, 1 Hold, 0 Sell.

As of

BUY
2
67%
HOLD
1
33%
SELL
0
0%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+14.35%
5Y+11.33%
3Y+7.34%
1Y−12.08%
TTM−6.40%

Net profit

Net profit growth by window
10Y+11.70%
5Y+2.28%
3Y+3.39%
1Y−29.49%
TTM−21.23%

Operating cash flow

Operating cash flow growth by window
10Y—
5Y+9.59%
3Y+2.38%
1Y+7.76%
TTM—

10Y: The statements do not go back far enough for this window.

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y−11.73 pp
5Y−17.43 pp
3Y−4.60 pp
1Y−6.52 pp
TTM−4.76 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2016₹276 Cr
Mar 2018₹340 Cr
Mar 2019₹436 Cr
Mar 2020₹512 Cr
Mar 2021₹617 Cr
Mar 2022₹713 Cr
Mar 2023₹853 Cr
Mar 2024₹1,017 Cr
Mar 2025₹1,200 Cr
Mar 2026₹1,055 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2016₹87.00 Cr
Mar 2018₹100 Cr
Mar 2019₹118 Cr
Mar 2020₹169 Cr
Mar 2021₹235 Cr
Mar 2022₹179 Cr
Mar 2023₹238 Cr
Mar 2024₹305 Cr
Mar 2025₹373 Cr
Mar 2026₹263 Cr

Analyst Forecasts

Forecast For
FY27 consensus · EBITDA
₹470 Cr +12.0% vs FY26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 28 Oct 2026
AI opinion · based on fundamentals
Risk medium

Concord Biotech Ltd trades at ₹1,268.5 as of 2026-10-28 with a market cap of ₹13,270.57 Cr and a PE of 47.09x on trailing earnings. The company is virtually debt-free (debt-to-equity of 0) but faces a notable deceleration in both revenue (TTM sales growth of -6%) and profitability (TTM profit growth of -20%), while its ROE has declined from a 3-year average of 18% to 12.86% in the latest period.

Bull Case 6
  • Zero debt on the balance sheet (debt-to-equity ratio of 0), providing significant financial flexibility and insulation from rising interest rate cycles
  • Consistent long-term revenue compounding with 10-year sales CAGR of 14% and 5-year sales CAGR of 11%, indicating a durable growth franchise in fermentation-based APIs
  • 10-year compounded profit growth of 11% demonstrates the company's ability to scale earnings over longer periods despite near-term softness
  • Healthy dividend payout ratio of 28.2% with a current dividend yield of 0.55%, reflecting shareholder-friendly capital allocation even while funding growth
  • ROCE of 16.7% indicates the business generates reasonable returns on total capital employed, supporting the case for underlying business quality
  • 3-year and 5-year ROE averages of 18% suggest the current 12.86% ROE may represent a cyclical trough rather than structural deterioration
Bear Case 8
  • TTM revenue has contracted by -6% and TTM profit has declined by -20%, signalling a sharp near-term deterioration in business momentum
  • PE of 47.09x on trailing earnings is elevated, especially given negative near-term earnings growth, implying the market is pricing in a recovery that may or may not materialise
  • ROE has dropped to 12.86% from a 3-year average of 18% and 5-year average of 18%, a meaningful compression in return on equity
  • High debtor days of 159 days indicate stretched receivables, tying up working capital and raising potential collection risk
  • 5-year compounded profit CAGR of just 1% shows earnings have essentially stagnated over a meaningful medium-term window despite 11% sales CAGR, pointing to margin pressure
  • Price-to-book ratio of 6.58x is rich for a company whose ROE has fallen to ~13%, implying the market assigns a premium not fully supported by current returns
  • 1-year stock CAGR of -17% reflects significant recent underperformance, with the market repricing expectations lower
  • 5-year sales growth of 11.3% is characterised as poor for a specialty pharma/biotech company operating in high-growth API segments

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

8d ago

TL;DR: Limited recent news flow for Concord Biotech with only a routine regulatory disclosure around the Q2FY27 trading window closure. No material headwinds or positive catalysts have emerged in the current batch of articles. The upcoming Q2FY27 results will be the next key event to watch for directional cues on earnings trajectory and growth outlook.

Neutral 1
  • Trading window closed for Q2FY27 Sep 28

    Concord Biotech closes its trading window from October 1, 2026, until 48 hours after declaring Q2FY27 financial results, restricting insider trading as per regulatory compliance.

Quarterly Results

₹ Cr
CONCORDBIO quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
195
262
241
319
216
310
244
430
204
247
278
326
261
312
Expenses
123
143
135
185
135
174
146
239
143
157
176
204
173
202
Operating Profit
72
119
106
134
81
137
98
190
61
91
102
122
87
110
OPM %
37%
45%
44%
42%
38%
44%
40%
44%
30%
37%
37%
38%
33%
35%
Other Income
7
8
8
11
10
10
15
9
14
13
7
16
13
10
Interest
1
1
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
13
13
14
14
13
13
13
15
18
18
19
19
18
18
PBT
65
113
100
131
78
133
99
185
57
86
90
118
82
102
Tax %
25%
25%
26%
26%
25%
26%
25%
23%
26%
26%
25%
24%
26%
26%
Net Profit
48
84
75
97
58
99
74
142
43
63
68
90
61
76
EPS (₹)
4.63
8.08
7.13
9.29
5.57
9.43
7.08
13.57
4.07
6.01
6.48
8.6
5.85
—

Sep 2026: from the results filed on 27 Oct 2026, ahead of the full statement, so some rows are blank.

Profit & Loss

₹ Cr
CONCORDBIO profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
239
276
340
436
512
617
713
853
1,017
1,200
1,055
1,112
Expenses
133
145
212
256
308
289
439
509
585
693
678
709
Operating Profit
105
131
127
180
205
328
274
344
432
507
377
402
OPM %
44%
48%
37%
41%
40%
53%
38%
40%
42%
42%
36%
36%
Other Income
11
8
36
17
31
14
23
35
34
44
49
49
Interest
1
0
1
1
1
1
6
5
3
1
1
0
Depreciation
10
10
18
19
21
28
50
54
54
54
74
75
PBT
106
129
144
178
213
313
241
320
409
496
351
376
Tax %
34%
33%
30%
33%
21%
25%
26%
26%
26%
25%
25%
—
Net Profit
70
87
100
118
169
235
179
238
305
373
263
282
EPS (₹)
6.93
8.61
9.61
11.32
16.15
22.5
17.07
22.76
29.13
35.65
25.17
26.94
Div. Payout %
22%
25%
0%
21%
22%
0%
3%
30%
30%
25%
30%
—

Balance Sheet

₹ Cr
CONCORDBIO balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
9
9
10
10
10
10
10
10
10
10
10
Reserves
268
329
585
673
761
990
1,098
1,282
1,515
1,802
2,009
Borrowings
35
36
22
9
52
89
62
32
10
3
1
Other Liabilities
55
74
69
71
118
94
144
191
164
219
216
Total Liabilities
367
448
685
763
941
1,183
1,313
1,515
1,699
2,034
2,237
Fixed Assets
104
110
189
230
240
546
573
593
575
795
786
CWIP
19
70
3
19
141
18
74
173
211
51
79
Investments
42
43
151
229
199
142
74
138
244
335
488
Other Assets
202
225
343
285
361
477
592
611
668
854
883
Total Assets
367
448
685
763
941
1,183
1,313
1,515
1,699
2,034
2,237

Cash Flow

₹ Cr
CONCORDBIO cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
—
—
79
—
155
167
207
246
265
245
264
Investing
—
—
−42
—
−114
−195
−112
−158
−155
−160
−142
Financing
—
—
−37
—
−43
31
−100
−85
−99
−99
−115
Net Cash Flow
—
—
0
—
−1
3
−4
3
12
−14
7
Free Cash Flow
—
—
79
—
−1
−37
52
101
180
134
169
CFO/EBITDA
—
—
101
—
100
74
98
92
85
70
96

Ratios

CONCORDBIO financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
165
182
236
133
131
105
119
117
125
159
159
Inventory Days
276
321
381
310
312
503
434
430
331
286
483
Days Payable
108
129
210
112
201
152
185
190
150
135
150
Cash Conversion Cycle
334
374
407
331
242
456
368
357
306
310
492
Working Capital Days
195
209
275
177
159
177
163
153
166
193
231
ROCE %
—
37%
—
25%
25%
32%
21%
26%
28%
28%
17%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Concord Biotech insights

65 extracted metrics across FY15–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 44.09%
  • Others 28.87%
  • DIIs 10.95%
  • Public 8.81%
  • FIIs 7.28%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Concord Biotech

What does Concord Biotech Ltd do?
Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.
Where is Concord Biotech Ltd (CONCORDBIO) listed?
Concord Biotech Ltd trades as CONCORDBIO on the NSE and under code 543960 on the BSE.
Which sector does Concord Biotech Ltd belong to?
Concord Biotech Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Concord Biotech Ltd?
Concord Biotech Ltd trades at a PE ratio of 24.33 as of 4 Nov 2026, on earnings per share of ₹26.94, against a book value of ₹198.42 per share.
What is the 52-week high and low of Concord Biotech Ltd?
Over the last 52 weeks Concord Biotech Ltd has traded between ₹493.5 and ₹807.5 as of 4 Nov 2026.
Does Concord Biotech Ltd pay dividends?
Concord Biotech Ltd has a dividend yield of 1.23%.
What is the Return on Equity (ROE) of Concord Biotech Ltd?
Concord Biotech Ltd reported a return on equity of 12.60%. Its debt-to-equity ratio is 0.00.

Company Information

Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.

Website concordbiotech.com
CEO Mr. Sudhir Jairam Vaid
Employees 1,571
Listed 18 Aug 2023
Face Value ₹1

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/CONCORDBIO.md for Concord Biotech Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month